Drug Trial Radar · NCT07759167
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Sep 17, 2026
Primary completion
Apr 2, 2027
Study completion Apr 2, 2027
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard anticoagulant treatment, such as heparin, to reduce the risk of blood clots as they can lead to serious health problems or be life-threatening. Because participants with ESKD who have hemodialysis have a higher risk of bleeding, the IMPs could be a meaningful new therapeutic option. The main aim of the study is to see what side effects may happen from taking REGN9933, REGN7508, or REGN9533. The study is looking at several other research questions, including: * How much IMP is in the blood at different times and * If the IMPs affect the ability of the blood to clot normally
Conditions
- End-Stage Kidney Disease (ESKD)
Interventions
REGN9933Drug
Administered per the protocol
REGN7508Drug
Administered per the protocol
REGN9533Drug
Administered per the protocol
HeparinDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 78 days
- Severity of TEAEsTime frame: Up to approximately 78 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.